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Key Points
• Endothelial cells carrying the
JAK2V617F mutation can be
detected both in the splenic
capillaries and in the splenic
vein of patients with myelofi-
brosis.
• The mutated endothelium may
be involved in the malignant
transformation of myelofibro-
sis, opening new perspectives
in its pathogenesis and treat-
ment.
Increased microvessel density contributes to abnormal BM and spleen microenviron-
ment in myelofibrosis (MF). Taking advantage of the JAK2V617F mutation as a marker of
malignancy, in the present study, we investigated whether splenic endothelial cells
(ECs) obtained from capillaries by laser microdissection or from fresh spleen tissue by
cell culture or cell sorting harbored such mutation in patients bearing the mutation in
their granulocytes and undergoing splenectomy for therapeutical reasons. To extend
the analysis to the ECs of large vessels, endothelial tissue from the splenic vein was
also studied. We found JAK2V617F ECs in 12 of 18 patients also bearing the mutation in
their granulocytes. In 3 patients, the mutation was found in at least 2 different EC
samples obtained by laser microdissection, cell culture, or cell sorting. The mutation
was detected in the splenic vein ECs of 1 of 6 patients investigated. In conclusion, we
provide evidence that some ECs from the spleen and splenic veins of patients with MF
bear the JAK2V617F mutation. We suggest that splenic ECs are involved in the process
of malignant transformation in MF. (Blood. 2013;121(2):360-368)
Introduction
Myelofibrosis (MF) is a neoplasm characterized by hematopoietic
stem cell–derived clonal myeloproliferation with cytokine-mediated
BM fibrosis and osteosclerosis.1 The clinical picture is dominated by
anemia, splenomegaly, and evolution toward blast transformation. BM
is characterized by global hyperplasia with clustering and dysplasia of
megakaryocytes and by constitutive reticulin or collagen fibrosis.2 The
molecular mechanisms responsible for the disease remain largely
unknown. An involvement of JAK2 signaling pathway by the gain-of-
function mutation V617F in exon 14 has been reported in approximately
60% of patients and additional abnormalities affecting other genes,
including MPL, TET-2, ASXL1, and EZH2, have been reported to
contribute to modifying the disease phenotype.3
Increased BM and spleen vascularity has been found to
represent a hallmark of the biology of MF.4,5 This event has been
documented to correlate with advanced-stage disease and poor
outcome.6 MF shares the neoangiogenesis mechanism with solid
tumors, in which the growth of malignant cells is strictly dependent
on the development of an adequate blood supply through sprouting
of new microvessels from preexisting capillaries.7
A classic concept in tumor angiogenesis is that tumor blood
vessels contain genetically normal and stable endothelial cells
(ECs), whereas tumors cells typically display genetic instability
and may harbor several genomic abnormalities. Recent studies,
however, have challenged this paradigm because evidence is
accumulating that in some cancers, ECs are derived from the tumor
itself and that the tumor-derived ECs share the same genetic
abnormalities with the malignant cells from which they originate.
Such evidence has been provided in hematologic neoplasms such
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as chronic myeloid leukemia,8,9 lymphoma,10 chronic lymphocytic
leukemia,11 myelodysplastic syndromes,12 and multiple my-
eloma13,14 and in solid tumors such as neuroblastoma,15
glioblastoma,16-19 and melanoma.20 Recently, using laser capture
microdissection followed by nested PCR or reverse-transcriptase
PCR, Sozer et al showed that ECs lining the lumen of terminal
hepatic venules from 3 patients with polycythemia vera and
concurrent Budd-Chiari syndrome harbored the JAK2V617F muta-
tion.21 These findings hinted at an identical mutation occurring in
both hematopoietic cells and ECs and led to the hypothesis that a
common progenitor of the 2 lineages, hemangioblasts,22 could
represent the target of neoplastic transformation.
In the present study, we have investigated for the first time the
JAK2V617F mutation in ECs derived from the spleen and the
splenic vein in patients with MF. Genomic anomalies of ECs in
patients with MF could be of biologic relevance given the role that
ECs play in the stem cell niche in both the BM and the spleen.
Moreover, given the high incidence of thrombosis in the splanchnic
area in patients with MF, genetic abnormalities of ECs might
influence the coagulation mechanism locally.
Methods
Patients
Spleen and peripheral blood samples were collected from 18 patients with
MF following a protocol approved by the institutional review boards for
human research of the Istituto di Ricovero e Cura a Carattere Scientifico
(IRCCS) Policlinico San Matteo Foundation (Pavia, Italy). At enrollment,
all patients gave written informed consent to be part of the study in
accordance with the Declaration of Helsinki. Eleven patients had primary
MF and the remaining patients had secondary MF after either polycythemia
vera or essential thrombocythemia. The patients were referred to the Center
for the Study of Myelofibrosis of the IRCCS Policlinico San Matteo
Foundation and received splenectomy from 2005-2011 either for transfusion-
dependent anemia and/or to relieve symptoms of massive splenomegaly.
EC isolation by laser pressure catapulting microdissection
from spleen capillaries
Laser pressure catapulting microdissection (for brevity, laser microdissec-
tion [LM]) was performed using a positioning and ablation with laser
microbeams (PALM) robot microbeam system (Zeiss) on 4-m-thick
silane- or polyethylene naphtholate-membrane–coated histologic spleen
sections. Slides were immunostained with either anti-CD34 (DBS) or
anti-CD31 (Dako Cytomation) mAbs, revealed using the streptavidin-biotin-
peroxidase–conjugated method (Dako), and finally counterstained with
Harris hematoxylin without coverslip. Sections were examined under an
inverted microscope (Axiovert 200, Zeiss) at different magnifications
(5, 10, 20, and 40) to identify CD34 or CD31 ECs derived from
proliferating splenic capillaries and the splenic vein (Figure 1A-C and
supplemental Figure 1, available on the Blood Web site; see the Supplemen-
tal Materials link at the top of the online article). These cells were selected
with either the “free drawing” or “predefined geometric elements” options.
To allow an accurate and clearcut definition of the targeted cells, laser
energy was properly calibrated according to the type of preparation. LM
was performed using the objective 40 LD-Arcoplan; both CD34 and
CD31 microdissected cells were harvested using a catapulting method
within the cap of the PCR tube. After a checkpoint function to find the
actual recovery of cells within the cap (Figure 1D), cells were digested in
appropriate lysis buffer (1 mM EDTA, pH 8.0, 20 mM Tris-HCl, pH 8.0,
0.5% Tween 20, and 400 g/mL of proteinase K) and processed under the
following conditions: 12 hours at 55°C, 10 minutes at 99°C, and 7 minutes
at 72°C. DNA samples were then subjected to molecular analysis.
Spleen ECFC and EC cultures
Spleen tissue specimens of 2-3 cm were obtained immediately after surgery,
washed extensively in PBS, further cut into smaller pieces, and reduced to a
single-cell suspension using a gentle MACS dissociator (Miltenyi Biotec).
Mononuclear cells (MNCs) were obtained by density gradient centrifuga-
tion. Endothelial colony-forming cells (ECFCs) were cultured according to
Ingram et al23 by plating at least 3 107 MNCs onto collagen-coated
30-mm Petri dishes (BD Biosciences) in the presence of the EGM-2 MV
medium (Lonza) at 37°C and 5% CO2. Nonadherent cells were discarded
after 2 days and thereafter medium was changed every 2-3 days. ECFCs
were observed after 12-15 days of culture and identified both on the basis of
their typical morphology (fast growing colonies with a cobblestone
Figure 1. Representative example of the LM tech-
nique for the isolation of mature ECs from the spleen.
(A-B) The photomicrographs showing the ECs of the
luminal surface of the splenic vein of patients 6 and
9, respectively, after immunohistochemical staining with
anti-CD34 mAb and counterstaining with Harris hematoxy-
lin. (C-D) Capillary of the splenic pulp immunostained
with anti-CD34 mAb (as in panels A and B) before (C) and
after (D) being laser microdissected and catapulted into
the cap of a PCR tube. Original magnification for panels
A, B, and C was 40 and for panel D, 10 using
LD-Arcoplan objectives. The microdissection laser sys-
tem is equipped on an inverted microscope (Axiovert
200; Zeiss) linked to a Sony DXC-309F 3CCD color video
camera.
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appearance) and on the expression of a peculiar immunophenotype
(CD105CD144CD146CD31VEGFR-2CD45CD14 cells), as de-
scribed previously.23 For culture of mature ECs, a maximum of 1  106
MNCs were plated onto 30-mm Petri dishes with the same medium used for
ECFCs. At the end of the culture period, the cells were recovered by
trypsinization and used for the evaluation of JAK2V617F mutational status
by PCR; for quantification of JAK2V617F, CD14, and CD45 expression by
RT-PCR; for DNA content assessment; and for estimation of hematopoietic
cell contamination by immunophenotype analysis. This was performed by
cytospinning 3-5 103 cells onto glass slides and staining by indirect
immunolabeling using secondary Abs conjugated with Alexa Fluor 488 (green)
or Alexa Fluor 594 (red) fluorochromes (Molecular Probes). As primary
Abs, anti-CD144 (Bender Med System), anti-CD31 and anti-VWF (both
Dako), and anti-CD45 (BD Biosciences) were used. At least 350 consecu-
tive cells were scored. Micrographs were captured at room temperature
using an Olympus IX71 inverted microscope equipped with a CPlan F1
10/0.30 objective, an Olympia Camedia C-3030 zoom with a 3 optical
plus 2.5 digital zoom (Olympus), and Camedia Master Version 2.0
software (Olympus).
Sensitivity to erythropoietin
To determine whether JAK2V617F ECs have an enhanced sensitivity to
erythropoietin, splenic ECs (from patient numbers 6, 13, and 17) were
incubated with increasing concentrations of erythropoietin (0, 0.1, 1, and
10 IU/mL) for up to 96 hours and the total cell number was assessed after
trypsinization. In addition, the effects of the same concentrations on
endothelial nitric oxide synthase (eNOS) expression were assessed as
described previously.24
Spleen EC purification by cell sorting
Isolation of spleen ECs was also determined by FACS. Splenic MNCs,
obtained as described in “Spleen ECFC and EC cultures,” were first
enriched by immunomagnetic cell selection using anti-CD34 microbeads
(Miltenyi Biotec). CD34-enriched cells were then stained with PE-
conjugated anti-CD146, FITC-conjugated anti-CD31, and APC-Cy7–
conjugated anti-CD45 mAbs and sorted on a FACSAria cell sorter (BD
Biosciences). Cells belonging to the hematopoietic lineage were excluded
according to CD45 surface marker expression. ECs were sorted according
to double positivity for the CD146 and CD31 markers (Figure 2).
Splenic vein EC separation
Small fragments of splenic vein (0.5-1.5 cm) were obtained from 11 patients
at the time of surgery. The vessel specimen was cut longitudinally and
opened with the endothelial lumen facing up. The surface was gently
washed twice with PBS without Ca and Mg and collagenase (1 mg/mL;
Sigma-Aldrich) was carefully dispensed on the endothelial surface. The
vein fragment was then incubated for 10-15 minutes at 37°C and 5% CO2,
followed by thorough washing of the luminal surface with PBS and EGM-2
medium. Finally, the washing medium, consisting of PBS and EGM-2
medium and containing ECs lining the lumen of the vein, was recovered,
pelleted by mild centrifugation, resuspended in EGM-2MV medium, and
cultured onto collagen-coated Petri dishes, as described in “Spleen ECFC
and EC cultures.”
Array-CGH
Molecular karyotyping of both granulocytes and ECs obtained in culture
was performed through array-comparative genomic hybridization (array-
CGH) using the Agilent 60K kit (Human Genome CGH Microarray;
Agilent Technologies) according to the manufacturer’s protocol. The
platform used is made up of 63 000 probes distributed along the whole
genome with an average spacing of 54.5 kb and a real average resolution of
approximately 150 kb. Data analysis was performed using Agilent Genomic
Workbench Standard Edition Version 6.5.0.58 software. Oligo positions
were in reference to hg19. A female poll reference DNA (Promega) was
used in all experiments.
JAK2V617F mutation detection by PCR and quantitative PCR
The mutational status for JAK2 of the spleen ECs obtained by LM, cell
culture, or cell sorting was determined using the BsaXI digestion
method as described previously25 (a detailed description is available in
supplemental Methods). JAK2V617F allele burden in the DNA of
Figure 2. Sorting strategy for the isolation of CD34CD146CD31CD45 cells from spleen-derived MNCs. Splenic MNCs were first enriched in CD34 cells by
immunomagnetic selection, followed by staining with anti-CD146, anti-CD31, and anti-CD45 mAbs, and then sorted according to CD34, CD31, and CD146 positive and CD45
negative expression. Contaminating platelets were excluded by size gating.
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granulocytes and in the RNA of ECs obtained in culture was measured
by allele-specific quantitative PCR, as described previously.26 The
JAK2V617F allele burden was calculated by comparison with a standard
curve obtained by mixing DNA from a patient with 100% allele burden
and that from a healthy subject in different proportions (2%, 5%, 12.5%,
25%, 50%, 75%, 95%, and 100%). To quantify the number of mutated
transcripts, a standard curve was obtained by mixing cDNA from a
patient 100% mutated with that from a healthy subject with the same
JAK2 expression levels.
RNA isolation and CD45/CD14 detection by RT-PCR
Total RNA was extracted from cultured ECs with the miRNeasy Mini Kit
(QIAGEN), purified from contaminating DNA by on-column digestion
with the RNase-free DNase Set (QIAGEN), according to the manufactur-
er’s instructions, and quantified with a Nanodrop 1000 spectrophotometer
(Thermo Scientific). cDNA synthesis was carried out using the iScript Kit
(Bio-Rad). In brief, 150 ng of each total RNA sample was reverse
transcribed using a blend of oligo-dT and random primers, diluted with
nuclease-free water to 3.75 ng/L (total RNA equivalent), and stored at
80°C. Primers for CD45 and CD14 for EvaGreen assays were designed
using the Beacon Designer Version 7.9 software (Premier Biosoft Interna-
tional; supplemental Table 1). Quantification of transcripts was carried
out in a 15-L reaction mixture containing 1 SsoFast EvaGreen
Supermix (Bio-Rad) and 400nM concentrations of each primer. The
PCR conditions were 95°C for 30 seconds, followed by 40 cycles of
95°C for 5 seconds and 60°C for 5 seconds. Melting curves were
generated after amplification in the range of 65-95°C with increments of
0.5°C every 5 seconds. For each experiment, 11.3 ng of cDNA was used
and each sample was tested in triplicate. The PCR data were collected
using the CFX96 Real-Time System (Bio-Rad) and data were analyzed
using qbasePLUS Version 2.11 software.
Analysis of DNA content
Cultured ECs were collected and, after the addition of a commercial
solution containing propidium iodide and RNAse (DNA QC Particles; BD
Biosciences), incubated for 30 minutes in the dark. At least 1.5 104 cells
were acquired on a FACSCalibur flow cytometer (BD Biosciences) and the cells’
DNA content was analyzed using the ModFit LT Version 3.0.3 software
program (Verity Software House).
Figure 3. JAK2V617F status of LM captured or cul-
tured ECs from spleen or splenic veins. Shown are
patient number 5 (lanes 3-6), patient number 6 (lanes
7-11 and 13), and patient number 9 (lane 12). Lane
1, JAK2V617F control; lane 2, JAK2 wild-type positive
control; and lane 14, negative control. MW indicates
molecular weight. Expected sizes for amplified fragments
after digestion with BsaIX are 141, 30, and 12 bp for the
wild-type allele, whereas the V617F allele remains undi-
gested (183 bp). Both the 30- and 12-bp fragments
derived from digestion of the wild-type alleles ran outside
the gel. Heterozygous samples show both 183-bp (mu-
tated) and 141-bp (wild-type) fragments.
Table 1. JAK2V617F mutation in ECs from spleen vessels
Patient
no.
JAK2V617F allele
burden of PMNs
JAK2V617F spleen
JAK2V617F
splenic vein
LM
ECs ECFCs SortingCD34 ECs CD31 ECs
1 48% 1Het/2WT/4NA 2Het/1WT/ ND ND ND ND
2 39% 3Het/1WT 3 Het ND ND ND ND
3 49% 1Het/1NA 1 Het/2WT NG WT ND ND
4 52% 2Het 2 Het/1NA ND ND ND ND
5 69% 1Hom/1Het2/WT 3 Het ND ND ND ND
6 81% 2Hom/3Het 1Hom/2Het Hom WT Hom Hom*
7 100% ND ND NG WT ND ND
8 34% 1Het/1WT 1Het/2WT Het NG ND ND
9 49% ND ND WT WT ND WT
10 60% ND ND NG WT ND WT
11 96% ND ND Het† NG ND WT
12 93% ND ND WT NG ND WT
13 78% ND ND WT NG ND NG
14 15% ND ND Het WT ND NG
15 65% ND ND Het WT ND NG
16 59% 2Hom/1Het/2WT 1Hom/1Het/1WT WT WT Het WT
17 65% ND ND Hom NG ND NG
18 45% ND ND NG NG ND NG
PMNs indicates polymorphonuclear cells; Het, heterozygous; Hom, homozygous; NA, not amplified; WT, wild-type; ND, not done; and NG, no growth. Numbers in the LM
column refer to the number of samples (approximately 100 ECs each) that displayed the reported genotype.
*Both ECs from LM (CD34 and CD31) and from in vitro culture displayed a homozygous genotype for JAK2V617F.
†This EC sample was contaminated by 30% CD45 cells.
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FISH analysis of ECs in spleen sections
FISH analysis was performed on deparaffinized spleen sections using an
anti-JAK2 probe (9p24; Kreatech Diagnostic) in a dual-color (red and
green) split assay on metaphase interphase spreads using a procedure
described previously.27
Results
Patient population
Fifteen patients were male and 3 were female with a median age of
62 years (range, 51-70), a median disease duration of 65 months
(range, 9-210), and a median disease severity score28 of 4 (range,
3-5). Median spleen weight was 3.6 kg (range, 2.2-4.6). Of
18 JAK2V617F-mutated patients, 11 had an allelic burden compat-
ible with a homozygous status in their granulocytes and 7 were
heterozygous. The assessment of the mutational status of hemato-
poiesis was performed at diagnosis and confirmed just before
splenectomy (Table 1). At the time of surgery, 5 patients had
cytogenetic analysis performed and all displayed a normal karyo-
type. No patients experienced splanchnic vein thrombosis before
splenectomy.
LM of spleen capillaries
Spleen ECs from 8 patients were obtained by LM. To minimize the
risk of contamination with hematopoietic cells, 2 set of spleen
sections were used for each patient; one was stained with an
anti-CD34 mAb (Figure 1) and the other was stained with an
anti-CD31 mAb (supplemental Figure 1). In either case, at least
50 capillaries per patient were microdissected by UV laser and
catapulted within the cap of a PCR tube (Figure 1), digested,
processed, and subjected to molecular analysis. The results of JAK2
mutational analysis are reported in Table 1 and a representative
example of the PCR results is shown in Figure 3. For staining with
anti-CD34, of a total of 32 samples analyzed (with a median
content of 100 ECs per sample), 18 showed the presence of the
JAK2V617F mutation, whereas in 8 samples, only wild-type alleles
were detected. In 6 samples, the PCR reaction failed. For CD31, of
24 samples analyzed, 17 samples contained the mutation, 6 did not,
and 1 sample was not amplified in the PCR reaction. All patients
had at least 1 sample of ECs positive for the JAK2 mutation, and
6 of 8 patients had at least 1 wild-type sample, suggesting a
different contribution of the mutated cells to the vessel wall.
A homozygous mutation was found in 7 samples of ECs in 3 of
4 patients with a homozygous mutation in their granulocytes.
Cultured ECs from the spleen
In 14 patients, we investigated freshly isolated cultured ECs
obtained from the spleen. Single-cell suspensions from spleen
fragments were plated onto collagen-coated Petri dishes in the
presence of EGM-2 medium. Mature cells with the morphology of
ECs (ie, flat, adherent, spindle-shaped cells) were observed starting
from 3-4 days of culture. These cells had a finite proliferative
capacity and stopped their growth within 10-14 days, at which time
they were trypsinized and divided in 3 aliquots. One aliquot
underwent PCR analysis for the detection of JAK2V617F mutation,
another was cytospun onto glass slides for EC purity evaluation by
immunocytochemistry, and the third aliquot was used for the
assessment of CD45 and CD14 RNA by RT-PCR. Mature ECs were
obtained from 10 of 14 patients in whom cultures were performed.
The V617F mutation was found in the samples of 6 different
patients, whereas in 4 patients, only wild-type alleles were
detectable. In 4 patients, no EC growth was observed (Table 1).
Assessment of CD45 cell contamination by immunocytochemis-
try showed the presence of 99.3%  0.09% CD144, 98.8%
 0.88% CD31, 97.8%  1.01% VWF, and 0.32%  0.07%
CD45 cells in 5 samples (Figure 4 and Table 2), whereas in
1 sample (patient number 11), contamination by 30% of CD45
hematopoietic cell contamination was demonstrated (Table 2),
indicating that the detection of the JAK2V617F mutation could be
because of contaminating hematopoietic cells. Concordant results
were obtained by RT-PCR, with CD45 and CD14 RNAs detectable
at a significant levels only in the sample that was contaminated by
CD45 cells by immunocytochemistry (not shown). In 3 of
5 patients in whom cultured ECs harbored the JAK2V617F
mutation (patient numbers 6, 8, and 15), JAK2V617F mRNA levels
were quantified by RT-PCR. In all 3 patients, the percentage of
mutated transcripts was equal to or greater (patient 6, 80%; patient
8, 83%; and patient 15, 78%) than the percentage of mutated alleles
in genomic DNA (patient 6, 81%; patient 8, 34%; and patient
15, 65%). In these same patients, DNA content analysis showed
that cells were 100% diploid (Figure 5A). In the other 2 patients
(patients 14 and 17), the limited number of cells recovered from the
culture precluded analysis of ploidy.
ECFCs were obtained from the splenic MNCs of 8 patients,
whereas in 6 patients, no ECFC growth was observed. The
Figure 4. Representative example of immunofluores-
cent analysis of cultured ECs from splenic MNCs of
patient number 6. ECs were detached from the culture
dish, cytospun onto a glass slide, and stained with
PE-conjugated anti–VE-cadherin mAb (red; A) and with
FITC-conjugated anti-CD45 mAb (green; B). MNCs from
the peripheral blood of a healthy subject were used as a
positive control for CD45 detection, and ECs derived
from ECFCs obtained from a healthy subject were used
as a positive control for VE-cadherin detection. Original
magnification was 250.
Table 2. Expression of endothelial (CD144, CD31, and VWF) and
hematopoietic (CD45) proteins by ECs isolated in culture from
splenic MNCs
Patient
no. CD144 CD31 VWF CD45
6 99.27 98.81 96.91 0.23
8 99.37 99.45 97.54 0.34
11 71.14 91.22 65.12 30.23
14 99.28 97.37 96.84 0.37
15 99.35 98.75 98.81 0.41
17 99.21 99.63 99.11 0.26
ECFCs 99.63 99.08 98.96 0.12
PB-MNCs 2.1 44.6 6.5 99.14
The percentage of positive cells is reported. At least 350 cells were scored per
Ab. ECFC-derived cells were used as a positive control for assessment of the
expression of EC-specific antigen and peripheral blood–derived MNCs from a
healthy donor were used as a positive control for CD45 expression.
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JAK2V617F mutation was never detected in a total of 23 colonies
investigated. In 3 of 5 patients in whom both ECFCs and mature
ECs were obtained from the same patients, the latter harbored the
mutation whereas the former did not (Table 1).
Sensitivity to erythropoietin
As shown in Table 3, no apparent differences in total cell number
was found between cultures without erythropoietin and cultures
with low concentrations (0.1 and 1 IU/mL) of erythropoietin.
A slight increase was observed when cells were incubated with
10 IU/mL of erythropoietin at later time points (72 and 96 hours of
incubation). These results were similar to those obtained when
nonmutated ECs were exposed to the same erythropoietin concen-
trations (not shown). With regard to eNOS expression, whereas a
3-fold increase was observed in the presence of 10 IU of
erythropoietin after 12 hours of incubation, no differences with
respect to control (no erythropoietin added) were observed at lower
concentrations (0.1 and 1 IU) at any time point tested (1, 4, and
12 hours).
Array-CGH
In 7 patients (patients 6, 8, 14, 15, 16, and 17), array-CGH was
performed to investigate the presence of cytogenetic alterations
both in granulocytes and in cultured ECs. Molecular karyotyping
showed the absence of chromosomal abnormalities in both types of
cells in all patients tested.
FACS-sorted ECs from the spleen
In 2 patients, FACS sorting was performed and CD146
CD31CD45 cells were obtained from immunomagnetically
selected splenic CD34 cells (Figure 2). In 2 of 2 samples
(obtained from patients homozygous for the mutation in their
granulocytes), the mutation was detected by PCR followed by
digestion with Bsa XI (Table 1). In one patient, only mutated alleles
were detected in the sorted ECs (Figure 6), whereas in the other,
both mutated and wild-type alleles were detected.
ECs from the splenic vein
In 11 patients, samples of the splenic vein were also obtained after
surgery and divided into 2 fragments; one was used immediately
for cell culture, as described in “Splenic vein EC separation”; and
the other was embedded in paraffin for LM experiments, as
described in “EC isolation and laser pressure catapulting microdis-
section from spleen capillaries.” ECs lining the inner vessel wall
were isolated both from the fresh fragment by digestion with
collagenase followed by in vitro culture, as described above, and
from the paraffin-embedded fragment by LM. Mature ECs were
obtained in culture in 6 patients and by LM in 2 other patients.
JAK2V617F cells were detected in 1 patient both in the culture-
derived and in the LM-derived samples (both after staining with
anti-CD34 and with anti–CD31-Abs), whereas in the cultures of the
remaining 5 patients, only the JAK2 gene in the wild-type status was
detected (Table 1). No evidence of CD45 cells was found in either
the cytospins or the RNA of ECs cultured from the JAK2V617F
sample (not shown).
FISH analysis of ECs in spleen sections
In 4 of 8 patients, FISH analysis with a probe specific for the JAK2
gene was performed (Figure 5). One hundred nuclei were counted
per section; 390 nuclei displayed a double signal (indicating 2 copies of
the JAK2 gene), 4 nuclei displayed 3 signals, and 3 nuclei
displayed 1 signal.
Discussion
In the present study, we provide evidence that ECs from either the
spleen or the splenic vein of patients with MF frequently share the
same genetic abnormality with the hematopoietic malignant cells:
the JAK2V617F mutation. The spleen is a critical organ in the
biology of MF featuring neoangiogenetic process that are strictly
related to the hematopoietic metaplastic tissue. The vasculature of
the spleen is complex, both in term of vessels and ECs. In fact, the
arterioles divide into capillaries and sinusoids with different
functions, and the EC-leaning capillaries and sinusoids are divided
into 2 main pools, either CD34 and CD8 or CD8 and CD34,
respectively. We approached the study of spleen ECs using
different methods for EC isolation. To avoid contamination of the
endothelial splenic samples by hematopoietic cells, we also used all
Figure 5. DNA content of cultured splenic ECs and
FISH analysis of ECs in spleen sections. (A) Represen-
tative example of DNA content analysis of JAK2V617F
ECs obtained from in vitro culture of splenic mononuclear
cells of patient number 6. Cells are 100% diploid. (B)
Representative microphotograph of FISH analysis of
ECs in a spleen section with a dual-color anti-JAK2
probe. Two cells, each with 2 green and 2 red signals
(arrows), are shown.
Table 3. Effects of different concentrations of erythropoietin on the
in vitro growth of JAK2V617F ECs
Incubation
time, h
Erythropoietin concentration, IU/mL
0 0.1 1 10
0 1  103 1  103 1  103 1  103
12 0.98  103 0.99  103 1.01  103 0.99  103
24 1.04  103 1.02  103 1.1  103 1.06  103
48 1.34  103 1.28  103 1.31  103 1.53  103
72 1.57  103 1.62  103 1.88  103 2.01  103
96 1.91  103 1.87  103 2.06  103 2.49  103
Results are the mean of the total cell number recovered from the cultures of the
mutated ECs of the 2 patients tested (patients 6 and 17) with increasing doses of
erythropoietin at different time points (see “Methods” for details).
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the operationally feasible controls. In particular, we used LM to
obtain both CD34 and CD31 EC-leaning capillaries and the
splenic vein. We also performed cultures of ECs from fragments of
fresh tissue to obtain all cells that had the properties necessary to
grow in vitro in endothelial medium and showing the morphology
and the immunophenotype of both mature endothelium and endo-
thelial progenitor cells. Finally, we also sorted cells with the
immunophenotype of ECs from the same splenic fresh tissue.
Altogether, 12 of 18 patients investigated for the mutation had
documentation of JAK2V617F-mutated ECs in splenic vessels, and
6 of 10 patients for whom ECs were cultured in vitro had
documentation of mutated ECs. In addition, in the 12 patients in
whom the mutation was found, the mutated ECs were found in a
great proportion of vessels. Finally, in contrast to a previous study
in which malignant endothelium was obtained in cells derived only
from microvessels,21 in the present study, we also found the JAK2
mutation in ECs derived from a large vessel such as the splenic
vein. It will be of great interest in future studies to investigate
whether mutated ECs could also be isolated from tissues other than
the spleen. However, ethical reasons prevent accessibility to
extra-hematopoietic and extra-splenic tissues, thus limiting the
possibility of searching for JAK2V617F ECs in organs not
involved in active neoangiogenesis (eg, the spleen of PMF patients)
and in large vessels other than the splenic vein. Moreover, the
absence of concomitant cytogenetic abnormalities in the hematopoi-
etic cells of patients at the time of splenectomy precluded the
possibility of also detecting them in splenic ECs.
An important finding of the present study is the mechanism by
which spleen ECs acquire the JAK2V617F mutation. Different
hypotheses may be raised. In animal models, the so-called angio-
genic monocytes contribute to neovessel formation, acquiring the
phenotype of mature ECs at sites of active neoangiogenesis.29 It is
possible that monocytes could play a similar role in MF and could
therefore be responsible for the detection of the JAK-2 mutation in
the splenic endothelium of our samples. However, in humans, it is
currently thought that angiogenic monocytes (or CFU-Hill) can
favor angiogenesis by secreting proangiogenic factors rather than
directly participating in neovessel formation or endothelium turn-
over.30 An alternative hypothesis is that ECFCs, which circulate at
high frequency in the peripheral blood of patients with MF,31 could
operate as progenitor cells in the mature endothelium. The exis-
tence of a common progenitor to endothelial and hematopoietic
cells in which the V617F mutation occurs could explain the
involvement of V617F ECs in the process of endotheliopoiesis
and endothelium renewal. However, we have repeatedly docu-
mented that circulating ECFCs lack the JAK2V617F mutation,32
and we further demonstrate herein its absence in the ECFCs
resident in the spleen. At variance with our observations, Teofili et
al have shown that ECFCs from patients with myeloproliferative
disorders can carry the JAK2V617F mutation, rendering it possible
that a mutated endothelium can derive from a mutated progenitor
cell.33 However, mutated ECFCs were detected only in patients
suffering from thrombotic events.33 The patients enrolled in our
study never experienced thrombosis and never showed mutated
ECFCs. Therefore, it seems unlikely that the mutated ECs that we
detected in the spleen of PMF patients could have derived from
mutated endothelial progenitor cells.
Two other mechanisms may potentially lead to the acquisition
of external DNA material into ECs of the spleen in patients with
MF. Cell fusion could account for JAK2V617F positivity of ECs if
a mutated hematopoietic cell has fused with an EC. In addition,
phagocytosis of cell-free JAK2V617F DNA or of JAK2V617F
apoptotic bodies by ECs could also account for the detection of the
mutation in splenic ECs, because it has been shown previously that
cell-free DNA circulates in the peripheral blood of cancer pa-
tients.34 Although we cannot rule out these events in a categorical
way, our findings of high levels of expression of JAK2V617F in
cultured ECs, the absence of aneuploidy and/or tetraploidy in the
same cells, and FISH analysis of ECs in spleen sections indicated
that no extra DNA was present in the samples that were found to
harbor the JAK2V617F mutation. Consistent with this assumption
are: (1) the high frequency of mutated ECs detected in our samples,
which makes the occurrence of cell fusion unlikely (in fact, we
never observed the presence of binucleated cells in ECs cultured in
vitro), and (2) the finding of ECs with the JAK2V617F mutation in
homozygosity, which makes the occurrence of cell-free DNA
phagocytosis very unlikely.
An intriguing hypothesis for explaining the presence of the
mutation in splenic ECs and splenic vein is that the MF stem cell
(which is a hematopoietic stem cell) actually represents the cell
giving rise to mutated endothelia. This event, which has been
described in glioblastoma16-19 and in neuroblastoma,15 would
assimilate the spleen of patient with MF to a solid tumor and would
justify the extension of the phenomenon to the microvessels and to
the large vessels of the spleen. It is currently a matter of debate
whether differentiation of tumor stem cells into ECs is orchestrated
by microenvironmental factors, by specific DNA reprogramming
of the neoplastic stem cells, or both.35 The existence of JAK2V617F
ECs could have important consequences in the physiopathology of
the disease. For example, considering the role that ECs play in the
organization and function of the stem cell niche, an altered vascular
niche in the spleen could be involved in determining both the
increased migratory behavior and the enhanced differentiative
predisposition that have been documented recently in CD34
hematopoietic progenitor cells derived from the spleen of PMF patients
compared with their peripheral blood–derived counterparts.36,37
Unexpectedly, no enhanced sensitivity to erythropoietin of
JAK2-mutated ECs was observed when proliferation and eNOS
synthase expression were assessed after exposure to low concentra-
tions of erythropoietin. However, the effects of erythropoietin on
Figure 6. JAK2V617 mutation in FACS-sorted splenic ECs from patient number
6. Splenic ECs show only mutated alleles, confirming the homozygosity found in the
circulating polymorphonuclear cells of this patient. The HEL cell line was used as a
positive control for the JAK2V617F mutation; the K562 cell line was used as a positive
control for the wild-type JAK2 gene. Amplified fragments, obtained as described in
“Methods” and in Baxter et al25 are shown before () and after () digestion with
BsaXI. The expected sizes for amplified fragments after digestion with BsaIX are 241,
189, and 30 bp for the wild-type allele; the V617F allele remained undigested (460
bp). The 30-bp fragment derived from the digestion of the wild-type alleles ran outside
the gel.
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ECs have been reported previously to be subtle and are controver-
sial.38 Therefore, it is possible that a deeper and more extensive
investigation (which was outside the scope of this work) will show
that the mutation really confers to mutated ECs an increased
sensitivity to erythropoietin.
Our work has several potential biases. First, the results obtained
by the LM technique suffer from the potential contamination of the
individually picked ECs by surrounding nonendothelial (hematopoi-
etic) cells. However, although we cannot formally rule it out,
contamination of CD34 or CD31 laser-microdissected ECs is
unlikely because LM allows accurate single-cell identification and
capture. Moreover, should contamination by surrounding cells take
place, it would only contaminate the pooled ECs with a minimal
number of non-ECs. This would result in negligible quantity of
DNA compared with that derived from true ECs. This consider-
ation makes even more unlikely that it was contamination in the EC
samples that caused them to be homozygous for the JAK2V617F
mutation. The issue of contamination by hematopoietic cells can
also be raised for the ECs derived from the in vitro culture. In these
experiments, however, we were able to reliably rule out a possible
contribution of contaminating hematopoietic cells either by quanti-
tative PCR for the CD45 and CD14 transcripts or by counting
CD45 cells by immunophenotype. In fact, neither CD45/CD14
RNA nor CD45 cells were observed in ECs cultured from the
spleen in 5 of 6 samples investigated. Further evidence that
contamination may not account for our results is the patient with
JAK2-mutated ECs both in the LM samples and in the in vitro
culture at the homozygous state, who had FACS-sorted
CD34CD146CD31CD45 ECs without evidence of wild-type
alleles in the PCR product.
The results of the present study strongly support the concept
that mature ECs carrying the JAK2V617F mutation can be detected
both in the splenic capillaries and in a large vessel of the splanchnic
area of patients with MF, providing new perspectives in our
understanding of the phenotype, evolution, and therapy of this
disorder that warrant careful investigations in future studies. Our
results also generate several unanswered questions, both at the
physiologic and clinical levels. For example, considering the high
frequency of splanchnic thrombotic events in MF patients,39 it
would be relevant to understand whether the malignant ECs are
thrombogenic.
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